We empower our customers to reveal insights in health and disease, identify markers to inform life decisions and accelerate the development of better therapies." title="" class="btn" data-container="body" data-html="true" data-id="120781" data-placement="top" data-toggle="popover" data-trigger="focus" style="color:#b3d4fc" tabindex="0" data-original-title="Fluidigm"> 7,021 7,009 32,961
Activities
Technologies
Entity types
Location
2 Tower Pl Suite 2000, South San Francisco, CA 94080, USA
South San Francisco
United States of America
Employees
Scale: 501-1000
Estimated: 946
Engaged corporates
8Added in Motherbase
3 years, 5 months agoProviding essential, standardized tools to accelerate breakthroughs in human health
Microfluidics | Cytometry | Imaging
Standard BioTools delivers the leading proteomic and multi-omic solutions that enable researchers to discover unique biological insights not accessible by other technologies.
Mass Cytometry, Tissue Imaging, NGS Library Prep, Genotyping, Gene Expression, Copy Number Variation, Real-Time PCR, and Single-Cell Genomics
We support the scientific community in the quest to solve unanswered challenges in health and disease across basic, translational and clinical research, including the fields of cancer, inflammatory diseases, immunotherapies and environmental monitoring. Harnessing the power of proprietary CyTOF® and microfluidics technologies, Fluidigm products provide comprehensive cell analysis aimed to elevate scientific data into actionable insights.
Corporate | Type | Tweets | Articles | |
---|---|---|---|---|
![]() J.P. Morgan Bank | J.P. Morgan Bank | Other 9 Jan 2025 | | |
![]() Illumina Biotechnology, Biotechnology Research | Illumina Biotechnology, Biotechnology Research | Other 13 Jan 2025 | | |
![]() Novartis Pharmaceutical, Pharmaceutical Manufacturing | Novartis Pharmaceutical, Pharmaceutical Manufacturing | Not capitalistic Not partnership Event 18 Apr 2016 | | |
![]() AstraZeneca Pharmaceutical, Pharmaceutical Manufacturing | AstraZeneca Pharmaceutical, Pharmaceutical Manufacturing | Other 9 May 2021 | | |
![]() European Bioinformatics Institute | EMBL-EBI Research, Software Development | European Bioinformatics Institute | EMBL-EBI Research, Software Development | Not capitalistic Not partnership Event 25 May 2016 | | |
![]() Illumina For Startups Startup accelerator & VC, Biotechnology, Biotechnology Research | Illumina For Startups Startup accelerator & VC, Biotechnology, Biotechnology Research | Other 26 May 2020 | | |
![]() Genopole Biotechnology, Biotechnology Research | Genopole Biotechnology, Biotechnology Research | Not capitalistic Not partnership Event 5 May 2019 | | |
![]() Nasdaq Finance, Financial Services | Nasdaq Finance, Financial Services | Other 20 Apr 2022 | |
Axis | Entities | ||||||||
---|---|---|---|---|---|---|---|---|---|
No similarities |
Proteomics is entering a transformative era, and we are excited to be collaborating with Illumina and pharma leaders on a new proteomics pilot program with the UK Biobank. The new Illumina Protein Prep NGS-based proteomics platform, powered by our SOMAmerTM technology, will provide deeper biological insights into this cohort. We look forward to sharing the data from this project with the research community later this year.
Read more about this collaboration at: https://lnkd.in/eFuum3ed
Learn about our work with biobanks around the world: https://lnkd.in/ejvBW5RV
#Proteomics #Illumina
Join us on January 30, at 2 PM JST to explore the latest advancements in understanding and managing immune-related adverse events (irAE) caused by immune checkpoint inhibitors (ICI).
In this webinar, hear from leading experts from the Graduate School of Medicine, Kyoto University:
Dr. Kosaku Murakami will share the results of his research using #multimodality analysis, including mass cytometry.
Dr. Shinobu Suzuki will introduce "Seeds-Hub," which highlights insights from CyTOFTM technology.
🔗 Register now to learn more: https://bit.ly/41DG2kW
#Webinar #CancerImmunotherapy #ClinicalImmunology #CyTOF #ImmuneCheckpointTherapy
Michael Egholm, President and CEO of Standard BioTools, will share a corporate presentation on January 16 at 9:45am PT at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco.
A live audio webcast will be available to investors and other interested parties on our Investor Relations page at Events & Presentations.
Tomorrow at the 2nd Annual T Cells in the Brain Symposium in New York, we have two very exciting poster presentations about #IMC and its use in #Neurodegeneration research.
Between 4:00 pm - 5:30 pm, James Pemberton and Nick Zabinyakov will be presenting:
❇️ "Deciphering Spatial Cellular Heterogeneity in Neurodegenerative Brain Pathology With Imaging Mass Cytometry."
Explore how whole slide imaging modes and single-cell analysis unravel the complex cellular composition of the neurodegenerative brain.
❇️ "Revealing the Heterogeneity of Glioblastoma Using High-Plex Imaging Mass Cytometry With Whole Slide Imaging Modes."
Learn how this research takes us closer to advanced diagnostic and therapeutic options for cancer stem cell differentiation.
If you’re in attendance, connect with us at the symposium!
Learn more about high-plex imaging in neurodegeneration research: https://lnkd.in/eUtE2-xX
#TCB2025 #Immunology
New year, new webinar! 👀
On January 22, join us for "Bridging the Gap: Insights from Mouse and Human Models in Pancreatic Cancer Research" featuring guest speaker Marco Erreni, PhD from Humanitas Research Hospital.
Register now! https://lnkd.in/esUcZK_V
08:00 PT | 11:00 ET | 16:00 GMT | 17:00 CET
You will learn:
✅ How Imaging Mass CytometryTM (IMCTM) helps assess cell abundance, distribution, and phenotypes in PDAC progression across murine models.
✅ The use of IMC to analyze 8 human PDAC tissues, uncovering insights into cancer-associated fibroblast clusters and molecular pathways.
✅ How integrating mouse and human model analyses provides a comprehensive understanding of tumor-immune-stroma interactions to shape future therapies.
#CancerResearch #Cytometry #IMC #Imaging